In­cyte says un­der-the-radar JAK in­hibitor clears a high bar for skin dis­or­der

In­cyte — the com­pa­ny be­hind Jakafi and Olu­mi­ant — wants to put a third JAK in­hibitor on the map.

Pre­sent­ing at the Eu­ro­pean Hidradeni­tis Sup­pu­ra­ti­va Foun­da­tion con­fer­ence …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.